4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors... Show more
FDMT broke above its upper Bollinger Band on June 06, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 35 similar instances where the stock broke above the upper band. In of the 35 cases the stock fell afterwards. This puts the odds of success at .
The 10-day RSI Indicator for FDMT moved out of overbought territory on June 10, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 20 similar instances where the indicator moved out of overbought territory. In of the 20 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where FDMT declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Momentum Indicator moved above the 0 level on July 08, 2025. You may want to consider a long position or call options on FDMT as a result. In of 78 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for FDMT just turned positive on July 09, 2025. Looking at past instances where FDMT's MACD turned positive, the stock continued to rise in of 43 cases over the following month. The odds of a continued upward trend are .
Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where FDMT advanced for three days, in of 227 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 140 cases where FDMT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. FDMT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.422) is normal, around the industry mean (17.292). P/E Ratio (0.000) is within average values for comparable stocks, (58.926). FDMT's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.456). Dividend Yield (0.000) settles around the average of (0.040) among similar stocks. FDMT's P/S Ratio (10000.000) is very high in comparison to the industry average of (271.367).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FDMT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Industry Biotechnology
A.I.dvisor indicates that over the last year, FDMT has been loosely correlated with IDYA. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if FDMT jumps, then IDYA could also see price increases.
Ticker / NAME | Correlation To FDMT | 1D Price Change % | ||
---|---|---|---|---|
FDMT | 100% | -1.61% | ||
IDYA - FDMT | 44% Loosely correlated | -1.40% | ||
BEAM - FDMT | 43% Loosely correlated | -3.95% | ||
CCCC - FDMT | 43% Loosely correlated | +12.06% | ||
RGNX - FDMT | 43% Loosely correlated | -4.19% | ||
CRSP - FDMT | 42% Loosely correlated | -3.73% | ||
More |